Genetic and biological drivers of prostate cancer disparities in Black men.
Journal
Nature reviews. Urology
ISSN: 1759-4820
Titre abrégé: Nat Rev Urol
Pays: England
ID NLM: 101500082
Informations de publication
Date de publication:
14 Nov 2023
14 Nov 2023
Historique:
accepted:
05
10
2023
medline:
15
11
2023
pubmed:
15
11
2023
entrez:
14
11
2023
Statut:
aheadofprint
Résumé
Black men with prostate cancer have historically had worse outcomes than white men with prostate cancer. The causes of this disparity in outcomes are multi-factorial, but a potential basis is that prostate cancers in Black men are biologically distinct from prostate cancers in white men. Evidence suggests that genetic and ancestral factors, molecular pathways involving androgen and non-androgen receptor signalling, inflammation, epigenetics, the tumour microenvironment and tumour metabolism are contributing factors to the racial disparities observed. Key genetic and molecular pathways linked to prostate cancer risk and aggressiveness have potential clinical relevance. Describing biological drivers of prostate cancer disparities could inform efforts to improve outcomes for Black men with prostate cancer.
Identifiants
pubmed: 37964070
doi: 10.1038/s41585-023-00828-w
pii: 10.1038/s41585-023-00828-w
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2023. Springer Nature Limited.
Références
Wang, L. et al. Prostate cancer incidence and mortality: global status and temporal trends in 89 countries from 2000 to 2019. Front. Public. Health 10, 811044 (2022).
pubmed: 35252092
pmcid: 8888523
doi: 10.3389/fpubh.2022.811044
Siegel, R. L., Miller, K. D., Wagle, N. S. & Jemal, A. Cancer statistics, 2023. CA Cancer J. Clin. 73, 17–48 (2023).
pubmed: 36633525
doi: 10.3322/caac.21763
Giaquinto, A. N. et al. Cancer statistics for African American/Black People 2022. CA Cancer J. Clin. https://doi.org/10.3322/caac.21718 (2022).
doi: 10.3322/caac.21718
pubmed: 36190501
Chowdhury-Paulino, I. M. et al. Racial disparities in prostate cancer among black men: epidemiology and outcomes. Prostate Cancer Prostatic Dis. 25, 397–402 (2021).
pubmed: 34475523
pmcid: 8888766
doi: 10.1038/s41391-021-00451-z
Conti, D. V. et al. Trans-ancestry genome-wide association meta-analysis of prostate cancer identifies new susceptibility loci and informs genetic risk prediction. Nat. Genet. 53, 65–75 (2021).
pubmed: 33398198
pmcid: 8148035
doi: 10.1038/s41588-020-00748-0
Moses, K. A., Orom, H., Brasel, A., Gaddy, J. & Underwood, W. III Racial/ethnic disparity in treatment for prostate cancer: does cancer severity matter? Urology 99, 76–83 (2017).
pubmed: 27667157
doi: 10.1016/j.urology.2016.07.045
Schwartz, K. et al. Interplay of race, socioeconomic status, and treatment on survival of patients with prostate cancer. Urology 74, 1296–1302 (2009).
pubmed: 19962532
doi: 10.1016/j.urology.2009.02.058
Odedina, F. T. et al. Prostate cancer disparities in black men of African descent: a comparative literature review of prostate cancer burden among black men in the United States, Caribbean, United Kingdom, and West Africa. Infect. Agent. Cancer 4, S2 (2009).
pubmed: 19208207
pmcid: 2638461
doi: 10.1186/1750-9378-4-S1-S2
Powell, I. J., Bock, C. H., Ruterbusch, J. J. & Sakr, W. Evidence supports a faster growth rate and/or earlier transformation to clinically significant prostate cancer in black than in white American men, and influences racial progression and mortality disparity. J. Urol. 183, 1792–1796 (2010).
pubmed: 20299055
doi: 10.1016/j.juro.2010.01.015
Thompson, I. et al. Association of African-American ethnic background with survival in men with metastatic prostate cancer. J. Natl Cancer Inst. 93, 219–225 (2001).
pubmed: 11158191
doi: 10.1093/jnci/93.3.219
Hoffman, R. M. et al. Racial and ethnic differences in advanced-stage prostate cancer: the Prostate Cancer Outcomes Study. J. Natl Cancer Inst. 93, 388–395 (2001).
pubmed: 11238701
doi: 10.1093/jnci/93.5.388
Du, X. L. et al. Racial disparity and socioeconomic status in association with survival in older men with local/regional stage prostate carcinoma: findings from a large community-based cohort. Cancer 106, 1276–1285 (2006).
pubmed: 16475208
doi: 10.1002/cncr.21732
Moul, J. W. et al. Prostate-specific antigen values at the time of prostate cancer diagnosis African-American men. JAMA 274, 1277–1281 (1995).
pubmed: 7563532
doi: 10.1001/jama.1995.03530160029029
Tiguert, R. et al. Racial differences and prognostic significance of tumor location in radical prostatectomy specimens. Prostate 37, 230–235 (1998).
pubmed: 9831219
doi: 10.1002/(SICI)1097-0045(19981201)37:4<230::AID-PROS4>3.0.CO;2-L
Sundi, D. et al. Pathological examination of radical prostatectomy specimens in men with very low risk disease at biopsy reveals distinct zonal distribution of cancer in black American men. J. Urol. 191, 60–67 (2014).
pubmed: 23770146
doi: 10.1016/j.juro.2013.06.021
Tsodikov, A. et al. Is prostate cancer different in black men? Answers from 3 natural history models. Cancer 123, 2312–2319 (2017).
pubmed: 28436011
doi: 10.1002/cncr.30687
Darst, B. F. et al. A rare germline HOXB13 variant contributes to risk of prostate cancer in men of African ancestry. Eur. Urol. 81, 458–462 (2022).
pubmed: 35031163
pmcid: 9018520
doi: 10.1016/j.eururo.2021.12.023
Darst, B. F. et al. A germline variant at 8q24 contributes to familial clustering of prostate cancer in men of African ancestry. Eur. Urol. 78, 316–320 (2020).
pubmed: 32409115
pmcid: 7805560
doi: 10.1016/j.eururo.2020.04.060
Okobia, M. N., Zmuda, J. M., Ferrell, R. E., Patrick, A. L. & Bunker, C. H. Chromosome 8q24 variants are associated with prostate cancer risk in a high risk population of African ancestry. Prostate 71, 1054–1063 (2011).
pubmed: 21557270
pmcid: 4422491
doi: 10.1002/pros.21320
Bock, C. H. et al. Results from a prostate cancer admixture mapping study in African-American men. Hum. Genet. 126, 637–642 (2009).
pubmed: 19568772
pmcid: 2975267
doi: 10.1007/s00439-009-0712-z
Han, D. et al. Susceptibility-associated genetic variation in NEDD9 contributes to prostate cancer initiation and progression. Cancer Res. 81, 3766–3776 (2021).
pubmed: 33632899
pmcid: 8286295
doi: 10.1158/0008-5472.CAN-20-3042
Conti, D. V. et al. Two novel susceptibility loci for prostate cancer in men of African ancestry. J. Natl Cancer Inst. 109, djx084 (2017).
pubmed: 29117387
pmcid: 5448553
doi: 10.1093/jnci/djx084
Bonilla, C., Hooker, S., Mason, T., Bock, C. H. & Kittles, R. A. Prostate cancer susceptibility loci identified on chromosome 12 in African Americans. PLoS ONE 6, e16044 (2011).
pubmed: 21358824
pmcid: 3040176
doi: 10.1371/journal.pone.0016044
Ricks-Santi, L. et al. p53 Pro72Arg polymorphism and prostate cancer in men of African descent. Prostate 70, 1739–1745 (2010).
pubmed: 20593380
pmcid: 3057117
doi: 10.1002/pros.21209
Taioli, E. et al. Multi-institutional prostate cancer study of genetic susceptibility in populations of African descent. Carcinogenesis 32, 1361–1365 (2011).
pubmed: 21705483
pmcid: 3165127
doi: 10.1093/carcin/bgr119
Han, Y. et al. Prostate cancer susceptibility in men of African ancestry at 8q24. J. Natl Cancer Inst. 108, djv431 (2016).
pubmed: 26823525
pmcid: 4948565
doi: 10.1093/jnci/djv431
Barnabas, N., Xu, L., Savera, A., Hou, Z. & Barrack, E. R. Chromosome 8 markers of metastatic prostate cancer in African American men: gain of the MIR151 gene and loss of the NKX3-1 gene. Prostate 71, 857–871 (2011).
pubmed: 21456068
doi: 10.1002/pros.21302
Robbins, C. et al. Confirmation study of prostate cancer risk variants at 8q24 in African Americans identifies a novel risk locus. Genome Res. 17, 1717–1722 (2007).
pubmed: 17978284
pmcid: 2099580
doi: 10.1101/gr.6782707
Amundadottir, L. T. et al. A common variant associated with prostate cancer in European and African populations. Nat. Genet. 38, 652–658 (2006).
pubmed: 16682969
doi: 10.1038/ng1808
Freedman, M. L. et al. Admixture mapping identifies 8q24 as a prostate cancer risk locus in African-American men. Proc. Natl Acad. Sci. USA 103, 14068–14073 (2006).
pubmed: 16945910
pmcid: 1599913
doi: 10.1073/pnas.0605832103
Haiman, C. A. et al. Characterizing genetic risk at known prostate cancer susceptibility loci in African Americans. PLoS Genet. 7, e1001387 (2011).
pubmed: 21637779
pmcid: 3102736
doi: 10.1371/journal.pgen.1001387
Haiman, C. A. et al. Multiple regions within 8q24 independently affect risk for prostate cancer. Nat. Genet. 39, 638–644 (2007).
pubmed: 17401364
pmcid: 2638766
doi: 10.1038/ng2015
Han, Y. et al. Generalizability of established prostate cancer risk variants in men of African ancestry. Int. J. Cancer 136, 1210–1217 (2015).
pubmed: 25044450
doi: 10.1002/ijc.29066
Walavalkar, K. et al. A rare variant of African ancestry activates 8q24 lncRNA hub by modulating cancer associated enhancer. Nat. Commun. 11, 3598 (2020).
pubmed: 32680982
pmcid: 7368061
doi: 10.1038/s41467-020-17325-y
Giorgi, E. E. et al. Fine-mapping IGF1 and prostate cancer risk in African Americans: the multiethnic cohort study. Cancer Epidemiol. Biomark. Prev. 23, 1928–1932 (2014).
doi: 10.1158/1055-9965.EPI-14-0333
Clark, A. S., West, K., Streicher, S. & Dennis, P. A. Constitutive and inducible Akt activity promotes resistance to chemotherapy, trastuzumab, or tamoxifen in breast cancer cells. Mol. Cancer Ther. 1, 707–717 (2002).
pubmed: 12479367
Faridi, J., Wang, L., Endemann, G. & Roth, R. A. Expression of constitutively active Akt-3 in MCF-7 breast cancer cells reverses the estrogen and tamoxifen responsivity of these cells in vivo. Clin. Cancer Res. 9, 2933–2939 (2003).
pubmed: 12912939
Yadav, S. et al. Somatic mutations in the DNA repairome in prostate cancers in African Americans and Caucasians. Oncogene 39, 4299–4311 (2020).
pubmed: 32300177
pmcid: 7239769
doi: 10.1038/s41388-020-1280-x
Yadav, S. et al. Contribution of inherited DNA-Repair gene mutations to hormone-sensitive and castrate-resistant metastatic prostate cancer and implications for clinical outcome. JCO Precis. Oncol. https://doi.org/10.1200/po.19.00067 (2019).
Chen, Z. et al. Diverse AR-V7 cistromes in castration-resistant prostate cancer are governed by HoxB13. Proc. Natl Acad. Sci. USA 115, 6810–6815 (2018).
pubmed: 29844167
pmcid: 6042123
doi: 10.1073/pnas.1718811115
Ye, S. et al. Clinical characterization of mismatch repair gene-deficient metastatic castration-resistant prostate cancer. Front. Oncol. 10, 533282 (2020).
pubmed: 33117677
pmcid: 7576180
doi: 10.3389/fonc.2020.533282
Norris, J. D. et al. The homeodomain protein HOXB13 regulates the cellular response to androgens. Mol. Cell 36, 405–416 (2009).
pubmed: 19917249
pmcid: 2788777
doi: 10.1016/j.molcel.2009.10.020
Pomerantz, M. M. et al. The androgen receptor cistrome is extensively reprogrammed in human prostate tumorigenesis. Nat. Genet. 47, 1346–1351 (2015).
pubmed: 26457646
pmcid: 4707683
doi: 10.1038/ng.3419
Na, R. et al. The HOXB13 variant X285K is associated with clinical significance and early age at diagnosis in African American prostate cancer patients. Br. J. Cancer 126, 791–796 (2022).
pubmed: 34799695
doi: 10.1038/s41416-021-01622-4
Plym, A. et al. DNA repair pathways and their association with lethal prostate cancer in African American and European American men. JNCI Cancer Spectr. 6, pkab097 (2022).
pubmed: 35079693
doi: 10.1093/jncics/pkab097
Krieger, K. L. et al. Repair-assisted damage detection reveals biological disparities in prostate cancer between African Americans and European Americans. Cancers 14, 1012 (2022).
pubmed: 35205762
pmcid: 8870190
doi: 10.3390/cancers14041012
Ledet, E. M. et al. Comparison of germline mutations in African American and Caucasian men with metastatic prostate cancer. Prostate 81, 433–439 (2021).
pubmed: 33792945
pmcid: 8252583
doi: 10.1002/pros.24123
Petrovics, G. et al. Increased frequency of germline BRCA2 mutations associates with prostate cancer metastasis in a racially diverse patient population. Prostate Cancer Prostatic Dis. 22, 406–410 (2019).
pubmed: 30542053
doi: 10.1038/s41391-018-0114-1
Southey, M. C. et al. PALB2, CHEK2 and ATM rare variants and cancer risk: data from COGS. J. Med. Genet. 53, 800–811 (2016).
pubmed: 27595995
doi: 10.1136/jmedgenet-2016-103839
Kaufman, B. et al. Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation. J. Clin. Oncol. 33, 244–250 (2015).
pubmed: 25366685
doi: 10.1200/JCO.2014.56.2728
Fong, P. C. et al. Inhibition of poly(ADP-Ribose) polymerase in tumors from BRCA mutation carriers. N. Engl. J. Med. 361, 123–134 (2009).
pubmed: 19553641
doi: 10.1056/NEJMoa0900212
Mateo, J. et al. DNA-repair defects and olaparib in metastatic prostate cancer. N. Engl. J. Med. 373, 1697–1708 (2015).
pubmed: 26510020
pmcid: 5228595
doi: 10.1056/NEJMoa1506859
Mateo, J. et al. Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial. Lancet Oncol. 21, 162–174 (2020).
pubmed: 31806540
pmcid: 6941219
doi: 10.1016/S1470-2045(19)30684-9
Hussain, M. et al. Survival with olaparib in metastatic castration-resistant prostate cancer. N. Engl. J. Med. 383, 2345–2357 (2020).
pubmed: 32955174
doi: 10.1056/NEJMoa2022485
Clarke, N. et al. Olaparib combined with abiraterone in patients with metastatic castration-resistant prostate cancer: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Oncol. 19, 975–986 (2018).
pubmed: 29880291
doi: 10.1016/S1470-2045(18)30365-6
Karzai, F. et al. Activity of durvalumab plus olaparib in metastatic castration-resistant prostate cancer in men with and without DNA damage repair mutations. J. Immunother. Cancer 6, 141 (2018).
pubmed: 30514390
pmcid: 6280368
doi: 10.1186/s40425-018-0463-2
Yu, E. Y. et al. Pembrolizumab plus olaparib in patients with metastatic castration-resistant prostate cancer: long-term results from the phase 1b/2 KEYNOTE-365 cohort a study. Eur. Urol. 83, 15–26 (2023).
pubmed: 36055895
doi: 10.1016/j.eururo.2022.08.005
Harlemon, M. et al. A custom genotyping array reveals population-level heterogeneity for the genetic risks of prostate cancer and other cancers in Africa. Cancer Res. 80, 2956–2966 (2020).
pubmed: 32393663
pmcid: 7335354
doi: 10.1158/0008-5472.CAN-19-2165
Zhang, W., Nicholson, T. & Zhang, K. Deciphering the polygenic basis of racial disparities in prostate cancer by an integrative analysis of genomic and transcriptomic data. Cancer Prev. Res. 15, 161–171 (2022).
doi: 10.1158/1940-6207.CAPR-21-0406
Pagadala, M. S. et al. Polygenic risk of any, metastatic, and fatal prostate cancer in the Million Veteran Program. J. Natl Cancer Inst. 115, 190–199 (2023).
pubmed: 36305680
doi: 10.1093/jnci/djac199
Kittles, R. A. et al. A common nonsense mutation in EphB2 is associated with prostate cancer risk in African American men with a positive family history. J. Med. Genet. 43, 507–511 (2006).
pubmed: 16155194
doi: 10.1136/jmg.2005.035790
Robbins, C. M., Hooker, S., Kittles, R. A. & Carpten, J. D. EphB2 SNPs and sporadic prostate cancer risk in African American men. PLoS ONE 6, e19494 (2011).
pubmed: 21603658
pmcid: 3095601
doi: 10.1371/journal.pone.0019494
Ruan, X., Huang, D., Huang, J., Xu, D. & Na, R. Application of European-specific polygenic risk scores for predicting prostate cancer risk in different ancestry populations. Prostate 83, 30–38 (2023).
pubmed: 35996327
doi: 10.1002/pros.24431
Adeloye, D. et al. An estimate of the incidence of prostate cancer in Africa: a systematic review and meta-analysis. PLoS ONE 11, e0153496 (2016).
pubmed: 27073921
pmcid: 4830589
doi: 10.1371/journal.pone.0153496
Huggins, C. & Hodges, C. V. Studies on prostatic cancer. I. The effect of castration, of estrogen and androgen injection on serum phosphatases in metastatic carcinoma of the prostate. CA Cancer J. Clin. 22, 232–240 (1972).
pubmed: 4625049
doi: 10.3322/canjclin.22.4.232
Weischenfeldt, J. et al. Integrative genomic analyses reveal an androgen-driven somatic alteration landscape in early-onset prostate cancer. Cancer Cell 23, 159–170 (2013).
pubmed: 23410972
doi: 10.1016/j.ccr.2013.01.002
Kim, H. S. et al. Prostate biopsies from black men express higher levels of aggressive disease biomarkers than prostate biopsies from white men. Prostate Cancer Prostatic Dis. 14, 262–265 (2011).
pubmed: 21519348
doi: 10.1038/pcan.2011.18
Gaston, K. E., Kim, D., Singh, S., Ford, O. H. 3rd & Mohler, J. L. Racial differences in androgen receptor protein expression in men with clinically localized prostate cancer. J. Urol. 170, 990–993 (2003).
pubmed: 12913756
doi: 10.1097/01.ju.0000079761.56154.e5
Wang, B. D. et al. Androgen receptor-target genes in African American prostate cancer disparities. Prostate Cancer 2013, 763569 (2013).
pubmed: 23365759
pmcid: 3556896
doi: 10.1155/2013/763569
Berchuck, J. E. et al. The prostate cancer androgen receptor cistrome in African American men associates with upregulation of lipid metabolism and immune response. Cancer Res. 82, 2848–2859 (2022).
pubmed: 35731919
pmcid: 9379363
doi: 10.1158/0008-5472.CAN-21-3552
Li, Y. et al. Regulation of a novel androgen receptor target gene, the cyclin B1 gene, through androgen-dependent E2F family member switching. Mol. Cell Biol. 32, 2454–2466 (2012).
pubmed: 22508987
pmcid: 3434485
doi: 10.1128/MCB.06663-11
Wikström, P., Marusic, J., Stattin, P. & Bergh, A. Low stroma androgen receptor level in normal and tumor prostate tissue is related to poor outcome in prostate cancer patients. Prostate 69, 799–809 (2009).
pubmed: 19189305
doi: 10.1002/pros.20927
Olapade-Olaopa, E. O. et al. Malignant transformation of human prostatic epithelium is associated with the loss of androgen receptor immunoreactivity in the surrounding stroma. Clin. Cancer Res. 5, 569–576 (1999).
pubmed: 10100708
Li, Y. et al. Decrease in stromal androgen receptor associates with androgen-independent disease and promotes prostate cancer cell proliferation and invasion. J. Cell Mol. Med. 12, 2790–2798 (2008).
pubmed: 18266956
pmcid: 3828892
doi: 10.1111/j.1582-4934.2008.00279.x
Koochekpour, S. et al. Androgen receptor mutations and polymorphisms in African American prostate cancer. Int. J. Biol. Sci. 10, 643–651 (2014).
pubmed: 24948877
pmcid: 4062957
doi: 10.7150/ijbs.8974
Zaman, N. et al. Proteomic-coupled-network analysis of T877A-androgen receptor interactomes can predict clinical prostate cancer outcomes between white (non-Hispanic) and African-American groups. PLoS ONE 9, e113190 (2014).
pubmed: 25409505
pmcid: 4237393
doi: 10.1371/journal.pone.0113190
Bennett, C. L. et al. Racial variation in CAG repeat lengths within the androgen receptor gene among prostate cancer patients of lower socioeconomic status. J. Clin. Oncol. 20, 3599–3604 (2002).
pubmed: 12202660
doi: 10.1200/JCO.2002.11.085
Powell, I. J. et al. The impact of CAG repeats in exon 1 of the androgen receptor on disease progression after prostatectomy. Cancer 103, 528–537 (2005).
pubmed: 15630701
doi: 10.1002/cncr.20788
Lange, E. M. et al. The androgen receptor CAG and GGN repeat polymorphisms and prostate cancer susceptibility in African-American men: results from the Flint Men’s Health Study. J. Hum. Genet. 53, 220–226 (2008).
pubmed: 18217192
pmcid: 2692543
doi: 10.1007/s10038-007-0240-4
Zeegers, M. P., Kiemeney, L. A., Nieder, A. M. & Ostrer, H. How strong is the association between CAG and GGN repeat length polymorphisms in the androgen receptor gene and prostate cancer risk? Cancer Epidemiol. Biomark. Prev. 13, 1765–1771 (2004).
doi: 10.1158/1055-9965.1765.13.11
Akinloye, O., Gromoll, J. & Simoni, M. Variation in CAG and GGN repeat lengths and CAG/GGN haplotype in androgen receptor gene polymorphism and prostate carcinoma in Nigerians. Br. J. Biomed. Sci. 68, 138–142 (2011).
pubmed: 21950206
doi: 10.1080/09674845.2011.11730341
Lunn, R. M., Bell, D. A., Mohler, J. L. & Taylor, J. A. Prostate cancer risk and polymorphism in 17 hydroxylase (CYP17) and steroid reductase (SRD5A2). Carcinogenesis 20, 1727–1731 (1999).
pubmed: 10469617
doi: 10.1093/carcin/20.9.1727
Wang, F., Zou, Y. F., Feng, X. L., Su, H. & Huang, F. CYP17 gene polymorphisms and prostate cancer risk: a meta-analysis based on 38 independent studies. Prostate 71, 1167–1177 (2011).
pubmed: 21656827
doi: 10.1002/pros.21332
Liu, W., Liu, R. & Wang, L. Androgen metabolism genes in prostate cancer health disparities. Cancer Health Disparities 1, e1–e6 (2017).
pubmed: 30756097
pmcid: 6368965
Shiina, M. et al. Differential expression of miR-34b and androgen receptor pathway regulate prostate cancer aggressiveness between African-Americans and Caucasians. Oncotarget 8, 8356–8368 (2017).
pubmed: 28039468
doi: 10.18632/oncotarget.14198
Theodore, S. C., Rhim, J. S., Turner, T. & Yates, C. MiRNA 26a expression in a novel panel of African American prostate cancer cell lines. Ethn. Dis. 20, 96–100 (2010).
Yang, Y. et al. Dysregulation of miR-212 promotes castration resistance through hnRNPH1-mediated regulation of AR and AR-V7: implications for racial disparity of prostate cancer. Clin. Cancer Res. 22, 1744–1756 (2016).
pubmed: 26553749
doi: 10.1158/1078-0432.CCR-15-1606
Caruso, R. P. et al. Altered N-myc downstream-regulated gene 1 protein expression in African-American compared with Caucasian prostate cancer patients. Clin. Cancer Res. 10, 222–227 (2004).
pubmed: 14734473
doi: 10.1158/1078-0432.CCR-0604-3
Kobayashi, A. et al. Bone morphogenetic protein 7 in dormancy and metastasis of prostate cancer stem-like cells in bone. J. Exp. Med. 208, 2641–2655 (2011).
pubmed: 22124112
pmcid: 3244043
doi: 10.1084/jem.20110840
Chang, C. A. et al. Ontogeny and vulnerabilities of drug-tolerant persisters in HER2
pubmed: 34911733
pmcid: 8983469
doi: 10.1158/2159-8290.CD-20-1265
Zhang, Z. et al. Loss of CHD1 promotes heterogeneous mechanisms of resistance to AR-targeted therapy via chromatin dysregulation. Cancer Cell 37, 584–598.e511 (2020).
pubmed: 32220301
pmcid: 7292228
doi: 10.1016/j.ccell.2020.03.001
Lim, S. C., Geleta, B., Maleki, S., Richardson, D. R. & Kovačević, Ž. The metastasis suppressor NDRG1 directly regulates androgen receptor signaling in prostate cancer. J. Biol. Chem. 297, 101414 (2021).
pubmed: 34785213
pmcid: 8668986
doi: 10.1016/j.jbc.2021.101414
Ross, R. et al. Serum testosterone levels in healthy young black and white men. J. Natl Cancer Inst. 76, 45–48 (1986).
pubmed: 3455741
Hsing, A. W. & Comstock, G. W. Serological precursors of cancer: serum hormones and risk of subsequent prostate cancer. Cancer Epidemiol. Biomark. Prev. 2, 27–32 (1993).
Wu, A. H. et al. Serum androgens and sex hormone-binding globulins in relation to lifestyle factors in older African-American, white, and Asian men in the United States and Canada. Cancer Epidemiol. Biomark. Prev. 4, 735–741 (1995).
Vidal, A. C. et al. Asian race and risk of prostate cancer: results from the REDUCE Study. Cancer Epidemiol. Biomark. Prev. 29, 2165–2170 (2020).
doi: 10.1158/1055-9965.EPI-20-0646
Massengill, J. C. et al. Pretreatment total testosterone level predicts pathological stage in patients with localized prostate cancer treated with radical prostatectomy. J. Urol. 169, 1670–1675 (2003).
pubmed: 12686805
doi: 10.1097/01.ju.0000062674.43964.d0
Ross, R. K. et al. 5-alpha-reductase activity and risk of prostate cancer among Japanese and US white and black males. Lancet 339, 887–889 (1992).
pubmed: 1348296
doi: 10.1016/0140-6736(92)90927-U
Mahal, B. A. et al. Racial differences in genomic profiling of prostate cancer. N. Engl. J. Med. 383, 1083–1085 (2020).
pubmed: 32905685
pmcid: 8971922
doi: 10.1056/NEJMc2000069
Rose, A. E. et al. Copy number and gene expression differences between African American and Caucasian American prostate cancer. J. Transl. Med. 8, 70 (2010).
pubmed: 20649978
pmcid: 2913940
doi: 10.1186/1479-5876-8-70
Liu, W. et al. Distinct genomic alterations in prostate tumors derived from African American men. Mol. Cancer Res. 18, 1815–1824 (2020).
pubmed: 33115829
doi: 10.1158/1541-7786.MCR-20-0648
Lindquist, K. J. et al. Mutational landscape of aggressive prostate tumors in African American men. Cancer Res. 76, 1860–1868 (2016).
pubmed: 26921337
pmcid: 4772140
doi: 10.1158/0008-5472.CAN-15-1787
Yuan, J. et al. Integrative comparison of the genomic and transcriptomic landscape between prostate cancer patients of predominantly African or European genetic ancestry. PLoS Genet. 16, e1008641 (2020).
pubmed: 32059012
pmcid: 7046294
doi: 10.1371/journal.pgen.1008641
Ali, H. E. A. et al. Dysregulated gene expression predicts tumor aggressiveness in African-American prostate cancer patients. Sci. Rep. 8, 16335 (2018).
pubmed: 30397274
pmcid: 6218553
doi: 10.1038/s41598-018-34637-8
Powell, I. J. et al. Genes associated with prostate cancer are differentially expressed in African American and European American men. Cancer Epidemiol. Biomark. Prev. 22, 891–897 (2013).
doi: 10.1158/1055-9965.EPI-12-1238
Khani, F. et al. Evidence for molecular differences in prostate cancer between African American and Caucasian men. Clin. Cancer Res. 20, 4925–4934 (2014).
pubmed: 25056375
pmcid: 4167562
doi: 10.1158/1078-0432.CCR-13-2265
Zhang, B., Yao, K. & Cheng, C. A network-based integration for understanding racial disparity in prostate cancer. Transl. Oncol. 17, 101327 (2022).
pubmed: 34998235
pmcid: 8738961
doi: 10.1016/j.tranon.2021.101327
Reams, R. R. et al. Microarray comparison of prostate tumor gene expression in African-American and Caucasian American males: a pilot project study. Infect. Agent. Cancer 4, S3 (2009).
pubmed: 19208208
pmcid: 2638462
doi: 10.1186/1750-9378-4-S1-S3
Wang, B. D. et al. Alternative splicing promotes tumour aggressiveness and drug resistance in African American prostate cancer. Nat. Commun. 8, 15921 (2017).
pubmed: 28665395
pmcid: 5497057
doi: 10.1038/ncomms15921
Olender, J. et al. A novel FGFR3 splice variant preferentially expressed in African American prostate cancer drives aggressive phenotypes and docetaxel resistance. Mol. Cancer Res. 17, 2115–2125 (2019).
pubmed: 31266816
pmcid: 6886680
doi: 10.1158/1541-7786.MCR-19-0415
Ha, S. & Wang, B.-D. Molecular insight into drug resistance mechanism conferred by aberrant PIK3CD splice variant in African American prostate cancer. Cancers 15, 1337 (2023).
pubmed: 36831678
pmcid: 9954641
doi: 10.3390/cancers15041337
Wang, Y. et al. Associations between RNA splicing regulatory variants of stemness-related genes and racial disparities in susceptibility to prostate cancer. Int. J. Cancer 141, 731–743 (2017).
pubmed: 28510291
pmcid: 5512873
doi: 10.1002/ijc.30787
George, D. J. et al. A prospective trial of abiraterone acetate plus prednisone in black and white men with metastatic castrate-resistant prostate cancer. Cancer 127, 2954–2965 (2021).
pubmed: 33951180
doi: 10.1002/cncr.33589
Castro, P. et al. Genomic profiling of prostate cancers from African American men. Neoplasia 11, 305–312 (2009).
pubmed: 19242612
pmcid: 2647733
doi: 10.1593/neo.81530
Reams, R. R. et al. Detecting gene-gene interactions in prostate disease in African American men. Infect. Agent. Cancer 6, S1 (2011).
pubmed: 21992608
pmcid: 3194179
doi: 10.1186/1750-9378-6-S2-S1
Koga, Y. et al. Genomic profiling of prostate cancers from men with African and European ancestry. Clin. Cancer Res. 26, 4651–4660 (2020).
pubmed: 32651179
pmcid: 7597977
doi: 10.1158/1078-0432.CCR-19-4112
Tosoian, J. J. et al. Prevalence and prognostic significance of PTEN loss in African-American and European-American men undergoing radical prostatectomy. Eur. Urol. 71, 697–700 (2017).
pubmed: 27477529
doi: 10.1016/j.eururo.2016.07.026
Troutman, S. M. et al. Racial disparities in the association between variants on 8q24 and prostate cancer: a systematic review and meta-analysis. Oncologist 17, 312–320 (2012).
pubmed: 22382457
pmcid: 3316915
doi: 10.1634/theoncologist.2011-0315
Blackburn, J. et al. TMPRSS2-ERG fusions linked to prostate cancer racial health disparities: a focus on Africa. Prostate 79, 1191–1196 (2019).
pubmed: 31090091
pmcid: 6617820
doi: 10.1002/pros.23823
Magi-Galluzzi, C. et al. TMPRSS2-ERG gene fusion prevalence and class are significantly different in prostate cancer of Caucasian, African-American and Japanese patients. Prostate 71, 489–497 (2011).
pubmed: 20878952
doi: 10.1002/pros.21265
Rosen, P. et al. Differences in frequency of ERG oncoprotein expression between index tumors of Caucasian and African American patients with prostate cancer. Urology 80, 749–753 (2012).
pubmed: 22950997
doi: 10.1016/j.urology.2012.07.001
Farrell, J. et al. Predominance of ERG-negative high-grade prostate cancers in African American men. Mol. Clin. Oncol. 2, 982–986 (2014).
pubmed: 25279185
pmcid: 4179793
doi: 10.3892/mco.2014.378
Yates, C., Long, M. D., Campbell, M. J. & Sucheston-Campbell, L. miRNAs as drivers of TMPRSS2-ERG negative prostate tumors in African American men. Front. Biosci. 22, 212–229 (2017).
doi: 10.2741/4482
Faisal, F. A. et al. Racial variations in prostate cancer molecular subtypes and androgen receptor signaling reflect anatomic tumor location. Eur. Urol. 70, 14–17 (2016).
pubmed: 26443432
doi: 10.1016/j.eururo.2015.09.031
Huang, F. W. et al. Exome sequencing of African-American prostate cancer reveals loss-of-function ERF mutations. Cancer Discov. 7, 973–983 (2017).
pubmed: 28515055
pmcid: 5836784
doi: 10.1158/2159-8290.CD-16-0960
García-Flores, M. et al. Clinico-pathological significance of the molecular alterations of the SPOP gene in prostate cancer. Eur. J. Cancer 50, 2994–3002 (2014).
pubmed: 25204806
doi: 10.1016/j.ejca.2014.08.009
Sweeney, C. et al. Ipatasertib plus abiraterone and prednisolone in metastatic castration-resistant prostate cancer (IPATential150): a multicentre, randomised, double-blind, phase 3 trial. Lancet 398, 131–142 (2021).
pubmed: 34246347
doi: 10.1016/S0140-6736(21)00580-8
Stopsack, K. H. et al. Differences in prostate cancer genomes by self-reported race: contributions of genetic ancestry, modifiable cancer risk factors, and clinical factors. Clin. Cancer Res. 28, 318–326 (2022).
pubmed: 34667026
doi: 10.1158/1078-0432.CCR-21-2577
Chernoff, J. The two-hit theory hits 50. Mol. Biol. Cell 32, rt1 (2021).
pubmed: 34735271
pmcid: 8694077
doi: 10.1091/mbc.E21-08-0407
Jaratlerdsiri, W. et al. Whole-genome sequencing reveals elevated tumor mutational burden and initiating driver mutations in African men with treatment-naïve, high-risk prostate cancer. Cancer Res. 78, 6736–6746 (2018).
pubmed: 30217929
doi: 10.1158/0008-5472.CAN-18-0254
Liu, W. et al. A CD24-p53 axis contributes to African American prostate cancer disparities. Prostate 80, 609–618 (2020).
pubmed: 32168400
pmcid: 7176538
doi: 10.1002/pros.23973
Elliott, B. et al. Ethnic differences in TGFβ-signaling pathway may contribute to prostate cancer health disparity. Carcinogenesis 39, 546–555 (2018).
pubmed: 29474521
pmcid: 5889036
doi: 10.1093/carcin/bgy020
Zhang, L. et al. MNX1 is oncogenically upregulated in African-American prostate cancer. Cancer Res. 76, 6290–6298 (2016).
pubmed: 27578002
pmcid: 5093064
doi: 10.1158/0008-5472.CAN-16-0087
Vidal, I. et al. GSTP1 positive prostatic adenocarcinomas are more common in black than white men in the United States. PLoS ONE 16, e0241934 (2021).
pubmed: 34191807
pmcid: 8244883
doi: 10.1371/journal.pone.0241934
Reams, R. R. et al. Immunohistological analysis of ABCD3 expression in Caucasian and African American prostate tumors. Biomed. Res. Int. 2015, 132981 (2015).
pubmed: 25802834
pmcid: 4329846
doi: 10.1155/2015/132981
Ferrari, M. G. et al. Identifying and treating ROBO1(-ve) /DOCK1(+ve) prostate cancer: an aggressive cancer subtype prevalent in African American patients. Prostate 80, 1045–1057 (2020).
pubmed: 32687658
pmcid: 7556361
doi: 10.1002/pros.24018
Parray, A. et al. ROBO1, a tumor suppressor and critical molecular barrier for localized tumor cells to acquire invasive phenotype: study in African-American and Caucasian prostate cancer models. Int. J. Cancer 135, 2493–2506 (2014).
pubmed: 24752651
pmcid: 4610361
doi: 10.1002/ijc.28919
Timofeeva, O. A. et al. Enhanced expression of SOS1 is detected in prostate cancer epithelial cells from African-American men. Int. J. Oncol. 35, 751–760 (2009).
pubmed: 19724911
Ganaie, A. A. et al. BMI1 drives metastasis of prostate cancer in Caucasian and African-American men and is a potential therapeutic target: hypothesis tested in race-specific models. Clin. Cancer Res. 24, 6421–6432 (2018).
pubmed: 30087142
pmcid: 6295260
doi: 10.1158/1078-0432.CCR-18-1394
Wang, Y. et al. RGS12 is a novel tumor-suppressor gene in African American prostate cancer that represses AKT and MNX1 expression. Cancer Res. 77, 4247–4257 (2017).
pubmed: 28611045
pmcid: 5559317
doi: 10.1158/0008-5472.CAN-17-0669
Wang, G. et al. MDM2 expression and regulation in prostate cancer racial disparity. Int. J. Clin. Exp. Pathol. 2, 353–360 (2009).
pubmed: 19158992
Yamoah, K. et al. Prostate tumors of native men from West Africa show biologically distinct pathways — A comparative genomic study. Prostate 81, 1402–1410 (2021).
pubmed: 34529278
pmcid: 8563425
doi: 10.1002/pros.24238
Wallace, T. A. et al. Tumor immunobiological differences in prostate cancer between African-American and European-American men. Cancer Res. 68, 927–936 (2008).
pubmed: 18245496
doi: 10.1158/0008-5472.CAN-07-2608
Awasthi, S. et al. Comparative genomics reveals distinct immune-oncologic pathways in African American men with prostate cancer. Clin. Cancer Res. 27, 320–329 (2021).
pubmed: 33037017
doi: 10.1158/1078-0432.CCR-20-2925
Rayford, W. et al. Comparative analysis of 1152 African-American and European-American men with prostate cancer identifies distinct genomic and immunological differences. Commun. Biol. 4, 670 (2021).
pubmed: 34083737
pmcid: 8175556
doi: 10.1038/s42003-021-02140-y
Eastham, J. A. et al. Clinical characteristics and biopsy specimen features in African-American and white men without prostate cancer. J. Natl Cancer Inst. 90, 756–760 (1998).
pubmed: 9605645
doi: 10.1093/jnci/90.10.756
Maynard, J. P. et al. Localization of macrophage subtypes and neutrophils in the prostate tumor microenvironment and their association with prostate cancer racial disparities. Prostate 82, 1505–1519 (2022).
pubmed: 35971807
doi: 10.1002/pros.24424
Rybicki, B. A. et al. Racial differences in the relationship between clinical prostatitis, presence of inflammation in benign prostate and subsequent risk of prostate cancer. Prostate Cancer Prostatic Dis. 19, 145–150 (2016).
pubmed: 26620738
doi: 10.1038/pcan.2015.54
Rundle, A. G. et al. Racial differences in the systemic inflammatory response to prostate cancer. PLoS ONE 16, e0252951 (2021).
pubmed: 34242232
pmcid: 8270440
doi: 10.1371/journal.pone.0252951
Vidotto, T. et al. Association of self-identified race and genetic ancestry with the immunogenomic landscape of primary prostate cancer. JCI Insight 8, e162409 (2023).
pubmed: 36752203
pmcid: 9977441
doi: 10.1172/jci.insight.162409
Chen, Y. et al. Breast and prostate cancers harbor common somatic copy number alterations that consistently differ by race and are associated with survival. BMC Med. Genomics 13, 116 (2020).
pubmed: 32819446
pmcid: 7441621
doi: 10.1186/s12920-020-00765-2
Powell, I. J., Chinni, S. R., Reddy, S. S., Zaslavsky, A. & Gavande, N. Pro-inflammatory cytokines and chemokines initiate multiple prostate cancer biologic pathways of cellular proliferation, heterogeneity and metastasis in a racially diverse population and underlie the genetic/biologic mechanism of racial disparity: update. Urol. Oncol. 39, 34–40 (2021).
pubmed: 32900629
doi: 10.1016/j.urolonc.2020.08.019
Teslow, E. A. et al. Exogenous IL-6 induces mRNA splice variant MBD2_v2 to promote stemness in TP53 wild-type, African American PCa cells. Mol. Oncol. 12, 1138–1152 (2018).
pubmed: 29741809
pmcid: 6026877
doi: 10.1002/1878-0261.12316
Mandal, S., Abebe, F. & Chaudhary, J. 174G/C polymorphism in the interleukin-6 promoter is differently associated with prostate cancer incidence depending on race. Genet. Mol. Res. 13, 139–151 (2014).
pubmed: 24446297
pmcid: 4038121
doi: 10.4238/2014.January.10.5
Hardiman, G. et al. Systems analysis of the prostate transcriptome in African-American men compared with European-American men. Pharmacogenomics 17, 1129–1143 (2016).
pubmed: 27359067
pmcid: 6040053
doi: 10.2217/pgs-2016-0025
Hawley, J. E. et al. Analysis of circulating immune biomarkers by race in men with metastatic castration-resistant prostate cancer treated with sipuleucel-T. J. Natl Cancer Inst. 114, 314–317 (2022).
pubmed: 34302463
doi: 10.1093/jnci/djab145
Sanchez, T. W. et al. Immunoseroproteomic profiling in African American men with prostate cancer: evidence for an autoantibody response to glycolysis and plasminogen-associated proteins. Mol. Cell Proteom. 15, 3564–3580 (2016).
doi: 10.1074/mcp.M116.060244
Dai, L. et al. Using serological proteome analysis to identify serum anti-nucleophosmin 1 autoantibody as a potential biomarker in European-American and African-American patients with prostate cancer. Prostate 76, 1375–1386 (2016).
pubmed: 27418398
doi: 10.1002/pros.23217
Sakiyama, M. J. et al. Race-associated expression of MHC class I polypeptide-related sequence A (MICA) in prostate cancer. Exp. Mol. Pathol. 108, 173–182 (2019).
pubmed: 31004600
doi: 10.1016/j.yexmp.2019.04.010
Vidal, A. C. et al. Racial differences in prostate inflammation: results from the REDUCE study. Oncotarget 8, 71393–71399 (2017).
pubmed: 29069714
doi: 10.18632/oncotarget.10690
Kinseth, M. A. et al. Expression differences between African American and Caucasian prostate cancer tissue reveals that stroma is the site of aggressive changes. Int. J. Cancer 134, 81–91 (2014).
pubmed: 23754304
doi: 10.1002/ijc.28326
Gillard, M. et al. Elevation of stromal-derived mediators of inflammation promote prostate cancer progression in African-American men. Cancer Res. 78, 6134–6145 (2018).
pubmed: 30181178
doi: 10.1158/0008-5472.CAN-17-3810
Sartor, O. et al. Survival of African-American and Caucasian men after sipuleucel-T immunotherapy: outcomes from the PROCEED registry. Prostate Cancer Prostatic Dis. 23, 517–526 (2020).
pubmed: 32111923
pmcid: 7423504
doi: 10.1038/s41391-020-0213-7
Weiner, A. B. et al. Plasma cells are enriched in localized prostate cancer in black men and are associated with improved outcomes. Nat. Commun. 12, 935 (2021).
pubmed: 33568675
pmcid: 7876147
doi: 10.1038/s41467-021-21245-w
Rai, R. et al. Epigenetic analysis identifies factors driving racial disparity in prostate cancer. Cancer Rep. 2, e1153 (2019).
doi: 10.1002/cnr2.1153
Kwabi-Addo, B. et al. Identification of differentially methylated genes in normal prostate tissues from African American and Caucasian men. Clin. Cancer Res. 16, 3539–3547 (2010).
pubmed: 20606036
doi: 10.1158/1078-0432.CCR-09-3342
Rubicz, R. et al. DNA methylation profiles in African American prostate cancer patients in relation to disease progression. Genomics 111, 10–16 (2019).
pubmed: 26902887
doi: 10.1016/j.ygeno.2016.02.004
Devaney, J. M. et al. Genome-wide differentially methylated genes in prostate cancer tissues from African-American and Caucasian men. Epigenetics 10, 319–328 (2015).
pubmed: 25864488
pmcid: 4622564
doi: 10.1080/15592294.2015.1022019
Apprey, V. et al. Association of genetic ancestry with DNA methylation changes in prostate cancer disparity. Anticancer. Res. 39, 5861–5866 (2019).
pubmed: 31704810
doi: 10.21873/anticanres.13790
Woodson, K., Hayes, R., Wideroff, L., Villaruz, L. & Tangrea, J. Hypermethylation of GSTP1, CD44, and E-cadherin genes in prostate cancer among US blacks and whites. Prostate 55, 199–205 (2003).
pubmed: 12692786
doi: 10.1002/pros.10236
Woodson, K., Hanson, J. & Tangrea, J. A survey of gene-specific methylation in human prostate cancer among black and white men. Cancer Lett. 205, 181–188 (2004).
pubmed: 15036650
doi: 10.1016/j.canlet.2003.11.027
Das, P. M. et al. Methylation mediated silencing of TMS1/ASC gene in prostate cancer. Mol. Cancer 5, 28 (2006).
pubmed: 16848908
pmcid: 1543653
doi: 10.1186/1476-4598-5-28
Chaudhary, A. K. et al. Mitochondrial dysfunction-mediated apoptosis resistance associates with defective heat shock protein response in African-American men with prostate cancer. Br. J. Cancer 114, 1090–1100 (2016).
pubmed: 27115471
pmcid: 4865976
doi: 10.1038/bjc.2016.88
Koochekpour, S., Marlowe, T., Singh, K. K., Attwood, K. & Chandra, D. Reduced mitochondrial DNA content associates with poor prognosis of prostate cancer in African American men. PLoS ONE 8, e74688 (2013).
pubmed: 24086362
pmcid: 3781126
doi: 10.1371/journal.pone.0074688
Xu, J. et al. Mitochondrial DNA copy number in peripheral blood leukocytes is associated with biochemical recurrence in prostate cancer patients in African Americans. Carcinogenesis 41, 267–273 (2020).
pubmed: 31408512
doi: 10.1093/carcin/bgz139
Kumar, R. et al. Cytochrome c deficiency confers apoptosome and mitochondrial dysfunction in African-American men with prostate cancer. Cancer Res. 79, 1353–1368 (2019).
pubmed: 30765600
pmcid: 6445777
doi: 10.1158/0008-5472.CAN-18-2383
Scott, T. A., Arnold, R. & Petros, J. A. Mitochondrial cytochrome c oxidase subunit 1 sequence variation in prostate cancer. Scientifica 2012, 701810 (2012).
pubmed: 24124627
pmcid: 3795349
doi: 10.6064/2012/701810
Gohlke, J. H. et al. Methionine-homocysteine pathway in African-American prostate cancer. JNCI Cancer Spectr. 3, pkz019 (2019).
pubmed: 31360899
pmcid: 6489686
doi: 10.1093/jncics/pkz019
Ramirez-Torres, A. et al. Racial differences in circulating mitochondria-derived peptides may contribute to prostate cancer health disparities. Prostate 82, 1248–1257 (2022).
pubmed: 35789022
pmcid: 9388542
doi: 10.1002/pros.24398
Xiao, J. et al. Low circulating levels of the mitochondrial-peptide hormone SHLP2: novel biomarker for prostate cancer risk. Oncotarget 8, 94900–94909 (2017).
pubmed: 29212276
pmcid: 5706922
doi: 10.18632/oncotarget.20134
McNally, E. J., Luncsford, P. J. & Armanios, M. Long telomeres and cancer risk: the price of cellular immortality. J. Clin. Invest. 129, 3474–3481 (2019).
pubmed: 31380804
pmcid: 6715353
doi: 10.1172/JCI120851
Heaphy, C. M. et al. Prostate cancer cell telomere length variability and stromal cell telomere length as prognostic markers for metastasis and death. Cancer Discov. 3, 1130–1141 (2013).
pubmed: 23779129
pmcid: 3797255
doi: 10.1158/2159-8290.CD-13-0135
Heaphy, C. M. et al. Racial difference in prostate cancer cell telomere lengths in men with higher grade prostate cancer: a clue to the racial disparity in prostate cancer outcomes. Cancer Epidemiol. Biomark. Prev. 29, 676–680 (2020).
doi: 10.1158/1055-9965.EPI-19-1462
Vaziri, H. & Benchimol, S. Reconstitution of telomerase activity in normal human cells leads to elongation of telomeres and extended replicative life span. Curr. Biol. 8, 279–282 (1998).
pubmed: 9501072
doi: 10.1016/S0960-9822(98)70109-5
Rybicki, B. A. et al. Race differences in telomere length in benign prostate biopsies and subsequent risk of prostate cancer. Cancer Epidemiol. Biomark. Prev. 31, 991–998 (2022).
doi: 10.1158/1055-9965.EPI-21-1221
Tsai, C. W. et al. Leukocyte telomere length is associated with aggressive prostate cancer in localized African American prostate cancer patients. Carcinogenesis 41, 1213–1218 (2020).
pubmed: 32614411
doi: 10.1093/carcin/bgaa070
Khan, S. et al. Racial differences in the expression of inhibitors of apoptosis (IAP) proteins in extracellular vesicles (EV) from prostate cancer patients. PLoS ONE 12, e0183122 (2017).
pubmed: 28981528
pmcid: 5628787
doi: 10.1371/journal.pone.0183122
deVere White, R. W. et al. Racial differences in clinically localized prostate cancers of black and white men. J. Urol. 159, 1979–1982 (1998).
pubmed: 9598502
doi: 10.1016/S0022-5347(01)63216-6
Steck, S. E. et al. Association between Plasma 25-Hydroxyvitamin D, ancestry and aggressive prostate cancer among African Americans and European Americans in PCaP. PLoS ONE 10, e0125151 (2015).
pubmed: 25919866
pmcid: 4412567
doi: 10.1371/journal.pone.0125151
Abd Elmageed, Z. Y. et al. High circulating estrogens and selective expression of ERβ in prostate tumors of Americans: implications for racial disparity of prostate cancer. Carcinogenesis 34, 2017–2023 (2013).
pubmed: 23658372
pmcid: 3765045
doi: 10.1093/carcin/bgt156
Rohrmann, S. et al. Serum estrogen, but not testosterone, levels differ between black and white men in a nationally representative sample of Americans. J. Clin. Endocrinol. Metab. 92, 2519–2525 (2007).
pubmed: 17456570
doi: 10.1210/jc.2007-0028
Williams, D. R., Priest, N. & Anderson, N. B. Understanding associations among race, socioeconomic status, and health: patterns and prospects. Health Psychol. 35, 407–411 (2016).
pubmed: 27018733
pmcid: 4817358
doi: 10.1037/hea0000242
Virolainen, S. J., VonHandorf, A., Viel, K., Weirauch, M. T. & Kottyan, L. C. Gene-environment interactions and their impact on human health. Genes. Immun. 24, 1–11 (2023).
pubmed: 36585519
doi: 10.1038/s41435-022-00192-6
Allen, L. et al. Socioeconomic status and non-communicable disease behavioural risk factors in low-income and lower-middle-income countries: a systematic review. Lancet Glob. Health 5, e277–e289 (2017).
pubmed: 28193397
pmcid: 5673683
doi: 10.1016/S2214-109X(17)30058-X
Major, J. M. et al. Socioeconomic status, healthcare density, and risk of prostate cancer among African American and Caucasian men in a large prospective study. Cancer Causes Control. 23, 1185–1191 (2012).
pubmed: 22674292
pmcid: 3405544
doi: 10.1007/s10552-012-9988-8
Oates, G. R. et al. Sociodemographic patterns of chronic disease: how the mid-south region compares to the rest of the country. Am. J. Prev. Med. 52, S31–s39 (2017).
pubmed: 27989290
pmcid: 5171223
doi: 10.1016/j.amepre.2016.09.004
Tehranifar, P. et al. Early life socioeconomic factors and genomic DNA methylation in mid-life. Epigenetics 8, 23–27 (2013).
pubmed: 23196856
pmcid: 3549876
doi: 10.4161/epi.22989
McGuinness, D. et al. Socio-economic status is associated with epigenetic differences in the pSoBid cohort. Int. J. Epidemiol. 41, 151–160 (2012).
pubmed: 22253320
doi: 10.1093/ije/dyr215
Muscatell, K. A., Brosso, S. N. & Humphreys, K. L. Socioeconomic status and inflammation: a meta-analysis. Mol. Psychiatry 25, 2189–2199 (2020).
pubmed: 31628416
doi: 10.1038/s41380-018-0259-2
Robinson, O. et al. Metabolic profiles of socio-economic position: a multi-cohort analysis. Int. J. Epidemiol. 50, 768–782 (2021).
pubmed: 33221853
doi: 10.1093/ije/dyaa188
Cheng, I. et al. Socioeconomic status and prostate cancer incidence and mortality rates among the diverse population of California. Cancer Causes Control. 20, 1431–1440 (2009).
pubmed: 19526319
pmcid: 2746891
doi: 10.1007/s10552-009-9369-0
Zeigler-Johnson, C. M., Tierney, A., Rebbeck, T. R. & Rundle, A. Prostate cancer severity associations with neighborhood deprivation. Prostate Cancer 2011, 846263 (2011).
pubmed: 22111000
pmcid: 3195845
doi: 10.1155/2011/846263
Tomlins, S. A. et al. Role of the TMPRSS2-ERG gene fusion in prostate cancer. Neoplasia 10, 177–188 (2008).
pubmed: 18283340
pmcid: 2244693
doi: 10.1593/neo.07822
Perner, S. et al. TMPRSS2:ERG fusion-associated deletions provide insight into the heterogeneity of prostate cancer. Cancer Res. 66, 8337–8341 (2006).
pubmed: 16951139
doi: 10.1158/0008-5472.CAN-06-1482
Song, C. & Chen, H. Predictive significance of TMRPSS2-ERG fusion in prostate cancer: a meta-analysis. Cancer Cell Int. 18, 177 (2018).
pubmed: 30459527
pmcid: 6233278
doi: 10.1186/s12935-018-0672-2
Kensler, K. H. et al. Variation in molecularly defined prostate tumor subtypes by self-identified race. Eur. Urol. Open. Sci. 40, 19–26 (2022).
pubmed: 35638091
pmcid: 9142751
doi: 10.1016/j.euros.2022.03.014
Li, J. et al. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 275, 1943–1947 (1997).
pubmed: 9072974
doi: 10.1126/science.275.5308.1943
Di Cristofano, A. & Pandolfi, P. P. The multiple roles of PTEN in tumor suppression. Cell 100, 387–390 (2000).
pubmed: 10693755
doi: 10.1016/S0092-8674(00)80674-1
Krohn, A. et al. Genomic deletion of PTEN is associated with tumor progression and early PSA recurrence in ERG fusion-positive and fusion-negative prostate cancer. Am. J. Pathol. 181, 401–412 (2012).
pubmed: 22705054
doi: 10.1016/j.ajpath.2012.04.026
Nakazawa, M. et al. Clinical and genomic features of SPOP-mutant prostate cancer. Prostate 82, 260–268 (2022).
pubmed: 34783071
doi: 10.1002/pros.24269
Shoag, J. et al. Prognostic value of the SPOP mutant genomic subclass in prostate cancer. Urol. Oncol. 38, 418–422 (2020).
pubmed: 32192889
doi: 10.1016/j.urolonc.2020.02.011
Swami, U. et al. SPOP mutations as a predictive biomarker for androgen receptor axis-targeted therapy in de novo metastatic castration-sensitive prostate cancer. Clin. Cancer Res. 28, 4917–4925 (2022).
pubmed: 36088616
doi: 10.1158/1078-0432.CCR-22-2228
Ng, K., Wilson, P., Mutsvangwa, K., Hounsome, L. & Shamash, J. Overall survival of black and white men with metastatic castration-resistant prostate cancer (mCRPC): a 20-year retrospective analysis in the largest healthcare trust in England. Prostate Cancer Prostatic Dis. 24, 718–724 (2021).
pubmed: 33479454
doi: 10.1038/s41391-020-00316-x
Marar, M. et al. Outcomes among African American and non-Hispanic white men with metastatic castration-resistant prostate cancer with first-line abiraterone. JAMA Netw. Open. 5, e2142093 (2022).
pubmed: 34985518
pmcid: 8733836
doi: 10.1001/jamanetworkopen.2021.42093
Leongamornlert, D. et al. Frequent germline deleterious mutations in DNA repair genes in familial prostate cancer cases are associated with advanced disease. Br. J. Cancer 110, 1663–1672 (2014).
pubmed: 24556621
pmcid: 3960610
doi: 10.1038/bjc.2014.30
Pritchard, C. C. et al. Inherited DNA-repair gene mutations in men with metastatic prostate cancer. N. Engl. J. Med. 375, 443–453 (2016).
pubmed: 27433846
pmcid: 4986616
doi: 10.1056/NEJMoa1603144
Gallagher, D. J. et al. Germline BRCA mutations denote a clinicopathologic subset of prostate cancer. Clin. Cancer Res. 16, 2115–2121 (2010).
pubmed: 20215531
pmcid: 3713614
doi: 10.1158/1078-0432.CCR-09-2871
Castro, E. et al. Germline BRCA mutations are associated with higher risk of nodal involvement, distant metastasis, and poor survival outcomes in prostate cancer. J. Clin. Oncol. 31, 1748–1757 (2013).
pubmed: 23569316
pmcid: 3641696
doi: 10.1200/JCO.2012.43.1882
Fizazi, K. et al. Rucaparib or physician’s choice in metastatic prostate cancer. N. Engl. J. Med. 388, 719–732 (2023).
pubmed: 36795891
pmcid: 10064172
doi: 10.1056/NEJMoa2214676
Agarwal, N. et al. TALAPRO-2: phase 3 study of talazoparib (TALA) + enzalutamide (ENZA) versus placebo (PBO) + ENZA as first-line (1L) treatment in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC). J. Clin. Oncol. 41, LBA17–LBA17 (2023).
doi: 10.1200/JCO.2023.41.6_suppl.LBA17
Chi, K. N. et al. Phase 3 MAGNITUDE study: first results of niraparib (NIRA) with abiraterone acetate and prednisone (AAP) as first-line therapy in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) with and without homologous recombination repair (HRR) gene alterations. J. Clin. Oncol. 40, 12–12 (2022).
doi: 10.1200/JCO.2022.40.6_suppl.012
Clarke, N. W. et al. Abiraterone and olaparib for metastatic castration-resistant prostate cancer. NEJM Evid. 1, EVIDoa2200043 (2022).
doi: 10.1056/EVIDoa2200043
Minas, T. Z. et al. Serum proteomics links suppression of tumor immunity to ancestry and lethal prostate cancer. Nat. Commun. 13, 1759 (2022).
pubmed: 35365620
pmcid: 8975871
doi: 10.1038/s41467-022-29235-2
Halabi, S. et al. Overall survival of black and white men with metastatic castration-resistant prostate cancer treated with docetaxel. J. Clin. Oncol. 37, 403–410 (2019).
pubmed: 30576268
doi: 10.1200/JCO.18.01279
Vaishampayan, U. N. et al. Clinical efficacy of enzalutamide vs bicalutamide combined with androgen deprivation therapy in men with metastatic hormone-sensitive prostate cancer: a randomized clinical trial. JAMA Netw. Open. 4, e2034633 (2021).
pubmed: 33496795
pmcid: 7838941
doi: 10.1001/jamanetworkopen.2020.34633
Tangen, C. M. et al. Improved overall survival trends of men with newly diagnosed M1 prostate cancer: a SWOG phase III trial experience (S8494, S8894 and S9346). J. Urol. 188, 1164–1169 (2012).
pubmed: 22921015
pmcid: 3481164
doi: 10.1016/j.juro.2012.06.046
Thatai, L. C., Banerjee, M., Lai, Z. & Vaishampayan, U. Racial disparity in clinical course and outcome of metastatic androgen-independent prostate cancer. Urology 64, 738–743 (2004).
pubmed: 15491712
doi: 10.1016/j.urology.2004.05.024
Nelson, W. G. et al. Health inequity drives disease biology to create disparities in prostate cancer outcomes. J. Clin. Invest. 132, e155031 (2022).
pubmed: 35104804
pmcid: 8803327
doi: 10.1172/JCI155031
Arenas-Gallo, C. et al. Race and prostate cancer: genomic landscape. Nat. Rev. Urol. 19, 547–561 (2022).
pubmed: 35945369
doi: 10.1038/s41585-022-00622-0